Logo image of AKYA

AKOYA BIOSCIENCES INC (AKYA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AKYA - US00974H1041 - Common Stock

1.29 USD
-0.07 (-5.15%)
Last: 7/7/2025, 8:00:00 PM
1.2899 USD
0 (-0.01%)
After Hours: 7/7/2025, 8:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to AKYA. AKYA was compared to 57 industry peers in the Life Sciences Tools & Services industry. AKYA has a bad profitability rating. Also its financial health evaluation is rather negative. AKYA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AKYA had negative earnings in the past year.
AKYA had a negative operating cash flow in the past year.
In the past 5 years AKYA always reported negative net income.
AKYA had a negative operating cash flow in each of the past 5 years.
AKYA Yearly Net Income VS EBIT VS OCF VS FCFAKYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -42.20%, AKYA is doing worse than 80.36% of the companies in the same industry.
Industry RankSector Rank
ROA -42.2%
ROE N/A
ROIC N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
AKYA Yearly ROA, ROE, ROICAKYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Gross Margin of AKYA (61.74%) is better than 82.14% of its industry peers.
In the last couple of years the Gross Margin of AKYA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for AKYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
AKYA Yearly Profit, Operating, Gross MarginsAKYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

0

2. Health

2.1 Basic Checks

AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
AKYA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AKYA has been increased compared to 5 years ago.
The debt/assets ratio for AKYA is higher compared to a year ago.
AKYA Yearly Shares OutstandingAKYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AKYA Yearly Total Debt VS Total AssetsAKYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

AKYA has an Altman-Z score of -4.23. This is a bad value and indicates that AKYA is not financially healthy and even has some risk of bankruptcy.
AKYA's Altman-Z score of -4.23 is on the low side compared to the rest of the industry. AKYA is outperformed by 89.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.23
ROIC/WACCN/A
WACC12.42%
AKYA Yearly LT Debt VS Equity VS FCFAKYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.61 indicates that AKYA may have some problems paying its short term obligations.
AKYA's Current ratio of 0.61 is on the low side compared to the rest of the industry. AKYA is outperformed by 98.21% of its industry peers.
A Quick Ratio of 0.40 indicates that AKYA may have some problems paying its short term obligations.
With a Quick ratio value of 0.40, AKYA is not doing good in the industry: 96.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.4
AKYA Yearly Current Assets VS Current LiabilitesAKYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.69% over the past year.
AKYA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.55%.
The Revenue has been growing by 14.10% on average over the past years. This is quite good.
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-14.55%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%

3.2 Future

AKYA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.11% yearly.
Based on estimates for the next years, AKYA will show a small growth in Revenue. The Revenue will grow by 7.53% on average per year.
EPS Next Y38.62%
EPS Next 2Y23.96%
EPS Next 3Y14.9%
EPS Next 5Y11.11%
Revenue Next Year4.99%
Revenue Next 2Y8.28%
Revenue Next 3Y7.01%
Revenue Next 5Y7.53%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AKYA Yearly Revenue VS EstimatesAKYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
AKYA Yearly EPS VS EstimatesAKYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKYA. In the last year negative earnings were reported.
Also next year AKYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKYA Price Earnings VS Forward Price EarningsAKYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKYA Per share dataAKYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

AKYA's earnings are expected to grow with 14.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.96%
EPS Next 3Y14.9%

More info and screens

0

5. Dividend

5.1 Amount

AKYA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (7/7/2025, 8:00:00 PM)

After market: 1.2899 0 (-0.01%)

1.29

-0.07 (-5.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners34.48%
Inst Owner Change-99.67%
Ins Owners4.15%
Ins Owner Change-127.1%
Market Cap64.44M
Revenue(TTM)79.96M
Net Income(TTM)-47.53M
Analysts50.91
Price Target1.45 (12.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.8%
Min EPS beat(2)-53.04%
Max EPS beat(2)-2.56%
EPS beat(4)1
Avg EPS beat(4)-13.87%
Min EPS beat(4)-53.04%
Max EPS beat(4)1.15%
EPS beat(8)3
Avg EPS beat(8)-8.79%
EPS beat(12)4
Avg EPS beat(12)-9.37%
EPS beat(16)5
Avg EPS beat(16)-10.77%
Revenue beat(2)0
Avg Revenue beat(2)-10.08%
Min Revenue beat(2)-18.23%
Max Revenue beat(2)-1.93%
Revenue beat(4)0
Avg Revenue beat(4)-12.79%
Min Revenue beat(4)-27.44%
Max Revenue beat(4)-1.93%
Revenue beat(8)3
Avg Revenue beat(8)-9.2%
Revenue beat(12)7
Avg Revenue beat(12)-5.07%
Revenue beat(16)10
Avg Revenue beat(16)-2.97%
PT rev (1m)-24.7%
PT rev (3m)-54.86%
EPS NQ rev (1m)6.19%
EPS NQ rev (3m)-5.47%
EPS NY rev (1m)8.52%
EPS NY rev (3m)-6.25%
Revenue NQ rev (1m)-0.75%
Revenue NQ rev (3m)-6.21%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-5.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS1.6
BVpS-0.12
TBVpS-0.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.74%
FCFM N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25%
Cap/Sales 2.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.4
Altman-Z -4.23
F-Score5
WACC12.42%
ROIC/WACCN/A
Cap/Depr(3y)58.71%
Cap/Depr(5y)73.75%
Cap/Sales(3y)5.54%
Cap/Sales(5y)6.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y38.62%
EPS Next 2Y23.96%
EPS Next 3Y14.9%
EPS Next 5Y11.11%
Revenue 1Y (TTM)-14.55%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%
Revenue Next Year4.99%
Revenue Next 2Y8.28%
Revenue Next 3Y7.01%
Revenue Next 5Y7.53%
EBIT growth 1Y35.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.58%
EBIT Next 3Y7.24%
EBIT Next 5Y9.43%
FCF growth 1Y48.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.89%
OCF growth 3YN/A
OCF growth 5YN/A

AKOYA BIOSCIENCES INC / AKYA FAQ

Can you provide the ChartMill fundamental rating for AKOYA BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 1 / 10 to AKYA.


Can you provide the valuation status for AKOYA BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to AKOYA BIOSCIENCES INC (AKYA). This can be considered as Overvalued.


How profitable is AKOYA BIOSCIENCES INC (AKYA) stock?

AKOYA BIOSCIENCES INC (AKYA) has a profitability rating of 1 / 10.


Can you provide the financial health for AKYA stock?

The financial health rating of AKOYA BIOSCIENCES INC (AKYA) is 0 / 10.